Evidence map›Paper›PMID 41665675›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

First-in-human evaluation of [

Xiaoai Wu, Yongzhao Xiang, Michael R Zalutsky, Ning Liu, Xin Li, Yong Du, Yutian Feng, Feize Li, Rong Tian

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoai Wu *Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-3518-9689
Yongzhao Xiang *Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
Michael R ZalutskyDepartment of Radiology, Duke University, Durham, USA.
Ning LiuKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, China.
Xin LiDepartment of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
Yong DuDepartment of Radiology, Johns Hopkins University, Baltimore, USA.
Yutian FengDepartment of Radiology, Duke University, Durham, USA.
Feize LiKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, China. lifeize@scu.edu.cn.ORCID 0000-0001-9255-3048
Rong TianDepartment of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China. rongtiannuclear@126.com.ORCID 0000-0002-5191-9004

Funding

National Natural Science Foundation of China 12475349NIH HHS CA184228Sichuan Province Science and Technology Support Program 2023NSFSC1714The State Administration of Science Technology and Industry for National Defense HNKFHBZ202322
6 · The paper itself

Abstract

purposeThe prostate-specific membrane antigen (PSMA) inhibitor [

methodsThe biodistribution of [

resultsPreliminary human dosimetry estimates based on murine data indicated that the kidneys received the highest dose (35.14 mGy/MBq). [

conclusions[

Indexed as

AstatineProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsAgedAnimalsHumansMaleMiceMiddle AgedNeoplasm MetastasisPositron Emission Tomography Computed TomographyRadiometryTissue DistributionAstatineAstatine-211Radiopharmaceuticals[211At]YF2Astatine-211Prostate-specific membrane antigenTargeted α-therapy

Identifiers

PMID41665675

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.